ICU logo

SEASTAR MEDICAL HOLDING CORP

ICUNASDAQ
๐Ÿ† #4975 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track ICU
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$5M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
123.6%
High Growth
๐Ÿ“ŠGross Margin
92.6%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
2.9x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for ICU.

Trading Snapshot

Day Range
โ€”
52-Week Range
$0.76 โ€“ $5.38
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
4.4M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$615,000
P/E Ratio
โ€”
P/S Ratio
2.9x
EPS (TTM)
$-3.93
Dividend Yield
โ€”
ICU logo

SEASTAR MEDICAL HOLDING CORP

ICU
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About SEASTAR MEDICAL HOLDING CORP

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.